Neurolixis Announces Publications Demonstrating Effects of NLX-112 in Parkinson's Disease Models
DANA POINT, Calif. - Feb. 22, 2016 - PRLog -- Neurolixis, Inc. announced the recent publication of two scientific articles demonstrating robust effects of the Company’s lead drug candidate, NLX-112, in rodent models of Parkinson’s disease. These studies were supported by grants received from The Michael J. Fox Foundation for Parkinson’s Research (MJFF), and were published in two high-profile, peer-reviewed journals:
The novel 5-HT1A receptor agonist, NLX-112, reduces L-DOPA-induced abnormal involuntary movements in rat: a chronic administration study with microdialysis measurements. McCreary AC, Varney MA, Newman-Tancredi A
Neuropharmacology. 2016 Jan 8. doi: 10.1016/j.neuropharm.2016.01.013.
NLX-112, a novel 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat. Iderberg H, McCreary AC, Varney MA, Kleven MS, Koek W, Bardin L, Depoortère R, Cenci MA, Newman-Tancredi A. Experimental Neurology, doi: 10.1016/j.expneurol.2015.05.021.
As described in these publications, NLX-112, a selective serotonin 5-HT1A receptor agonist, exhibited potent activity in parkinsonian rats, producing an immediate and complete abolition of L-DOPA-induced dyskinesia (LID). Furthermore, the anti-dyskinetic activity of NLX-112 was maintained with repeated administration, suggesting a sustained capacity to suppress or eliminate dyskinesias.
Adrian Newman-Tancredi, Ph.D., D.Sc., Chief Scientific Officer of Neurolixis, commented, "We are excited about the remarkable activity of NLX-112 in rodent models of LID. If these striking preclinical data translate to the clinic, NLX‑112 could significantly alleviate the troubling dyskinesia that prevent many Parkinson’s disease patients from performing routine daily tasks, thereby improving their quality of life. We look forward to initiating a Phase 2 clinical study with NLX-112 in Parkinson’s disease patients later this year.”
NLX-112 (also known as befiradol) acts on the brain’s serotonin system and is a particularly selective, high-efficacy agonist at 5-HT1A receptors. By targeting these receptors on serotonergic neurons, NLX-112 inhibits the development of LID. NLX-112 is an orally-administered agent that has previously been tested in over 500 human subjects, and Neurolixis plans to investigate its ability to reverse LID in patients with Parkinson’s disease later this year.
About L-DOPA-induced Dyskinesia (LID)
LID are involuntary movements without purpose that commonly occur in Parkinson’s patients after several years of treatment with dopamine replacement therapies such as L-DOPA. LID can become severely disabling, with patients often unable to perform routine daily tasks. As Parkinson's disease advances, the symptoms of LID worsen in frequency and severity. The presence of LID can restrict the dosing of L-DOPA, which may result in inadequate control of parkinsonian symptoms. There is no approved drug therapy for LID, and the effective treatment of LID remains a high unmet need in the Parkinson’s community.
About Neurolixis, Inc.
Neurolixis, located in Dana Point, California, is a privately held biotechnology company developing therapies for disorders of the central nervous system. The Company has two clinical programs: NLX-112 is a Phase 2-ready program targeting LID, and NLX-101 is a Phase 1 drug candidate targeting Rett syndrome. Additional discovery programs are targeting psychiatric disorders such as depression and schizophrenia. Further information is available at http://www.neurolixis.com.
About The Michael J. Fox Foundation
As the world’s largest non-profit funder of Parkinson’s research, The Michael J. Fox Foundation is dedicated to accelerating a cure for Parkinson’s disease and improved therapies for those living with the condition today. The Foundation pursues its goals through an aggressively funded, highly targeted research program coupled with active global engagement of scientists, Parkinson’s patients, business leaders, clinical trial participants, donors and volunteers. In addition to funding more than $525 million in research to date, the Foundation has fundamentally altered the trajectory of progress toward a cure. Operating at the hub of worldwide Parkinson’s research, the Foundation forges groundbreaking collaborations with industry leaders, academic scientists and government research funders; increases the flow of participants into Parkinson’s disease clinical trials with its online tool, Fox Trial Finder; promotes Parkinson’s awareness through high-profile advocacy, events and outreach; and coordinates the grassroots involvement of thousands of Team Fox members around the world. For more information, visit us on Facebook, Twitter, the Web and LinkedIn.
Forward Looking Statement
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including: our dependence on third parties for the development, regulatory approval and successful commercialization of our products, the inherent risk of failure in developing product candidates based on new technologies, risks associated with the costs of clinical development efforts, as well as other risks. Actual results may differ materially from those projected. These forward-looking statements represent our judgment as of the date of the release. Neurolixis disclaims any intent or obligation to update these forward-looking statements.